Related Experiment Video
Updated: Mar 25, 2026
08:33
Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay
Published on: June 25, 2019
8.8K
Relationship between uric acid levels and progressive supranuclear palsy.
David M Brody1, Irene Litvan1,2, Steve Warner
1Movement Disorder Center, Department of Neurosciences, University of California San Diego, San Diego, California, USA.
Movement Disorders : Official Journal of the Movement Disorder Society
|February 19, 2016
Summary
Serum uric acid levels do not appear to protect against Progressive Supranuclear Palsy (PSP). This study found no significant difference in uric acid levels between PSP patients and healthy controls.
Area of Science:
- Neuroscience
- Biochemistry
Background:
- Progressive Supranuclear Palsy (PSP) and Parkinson's Disease (PD) share a pro-oxidant pathophysiology.
- Uric acid, a marker of oxidative stress, is linked to a reduced risk and slower progression in PD.
Purpose of the Study:
- To investigate if low serum uric acid concentrations are associated with PSP.
- To determine if uric acid plays a protective role in PSP.
Main Methods:
- Serum uric acid levels were measured in 75 PSP cases and 75 matched healthy controls.
- Statistical analyses included logistic regression, chi-squared tests, and ANOVA.
- Disease severity was assessed using PSP-Rating Scale, UPDRS, and Mattis Dementia Rating Scale.
Main Results:
- Mean uric acid levels were similar between PSP cases (4.0 mg/dL) and controls (4.1 mg/dL).
- No statistically significant differences in uric acid levels were found between groups after controlling for sex.
- Uric acid levels did not correlate with PSP disease severity.
Conclusions:
- This study found no evidence that uric acid has a protective role in PSP.
- The results suggest no direct association between serum uric acid levels and PSP.
- A small inverse association cannot be entirely ruled out.
Related Concept Videos
01:15Parkinson's Disease: Overview
2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
60
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
60
01:22Lysosomal Hydrolases
4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
01:37Neural Regulation
44.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.7K
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
649
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
649